Overview

This trial is active, not recruiting.

Condition coronary disease
Sponsor Saint Michael's Medical Center
Start date May 2012
End date April 2014
Trial size 100 participants
Trial identifier NCT01609569, #09/12

Summary

The aim of this study is to determine on preliminary basis weather an elevated pro-calcitonin level can be used to assess ischemia as a result of coronary artery complications during percutaneous coronary intervention (PCI).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective
Arm
patients with coronary complication and patients without coronary complications. pro-calcitonin will be measured in both groups to see if any correlation.

Primary Outcomes

Measure
Pro-calcitonin blood level
time frame: "0,24 hours post cardiac intervention"

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - patients older than 18 years old. Exclusion Criteria: - no consent. - suspicion of sepsis. - Patients with elevated troponin or procalcitonin before enrollment. - patients who had non-elective angioplasty (e.g. rescue angioplasty, primary angioplasty, salvage angioplasty, or emergency angioplasty)

Additional Information

Official title Utility of Pro-calcitonin as an Indicator of Ischemia in Patients Undergoing Percutaneous Coronary Intervention With Subsequent Coronary Complications.
Principal investigator Habib Habib, MD
Description Pro-calcitonin is a type of protein found in the blood. This protein has recently be found to be elevated in patients with diseases of the arteries of the heart such as heart attack. Percutaneous coronary intervention (PCI) is widely used in the treatment of many patients with blockage in the arteries of the heart. the investigators normally used a marker called troponin after cardiac catheterization. However, this marker may not be specific. Pro-calcitonin has been found to be a useful marker for the detection of myocardial injury. the value of Pro-calcitonin as a marker for the identification of myocardial damage undergoing PCI has not yet been studied.
Trial information was received from ClinicalTrials.gov and was last updated in February 2013.
Information provided to ClinicalTrials.gov by Saint Michael's Medical Center.